Erasca

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2018-01-01

Employees: 126

Market Cap: $768.4M

Website: http://www.erasca.com

Introduction: Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 1, 2018 and is headquar...

Clinical Trials

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Phase 3

Recruiting

Conditions: Advanced or Metastatic NRAS-mutant Melanoma

Interventions: Drug: Naporafenib
Drug: Dacarbazine
Drug: Trametinib
Drug: Temozolomide

First Posted Date: 2024-04-03

Last Posted Date: 2024-12-18

Lead Sponsor: Erasca, Inc.

Target Recruit Count: 470

Registration Number: NCT06346067

Locations: 🇺🇸
Texas Oncology- Austin Midtown, Austin, Texas, United States
🇺🇸
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 42 locations

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

Phase 1

Recruiting

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Drug: Naporafenib
Drug: Trametinib

First Posted Date: 2023-06-18

Last Posted Date: 2024-07-26

Lead Sponsor: Erasca, Inc.

Target Recruit Count: 115

Registration Number: NCT05907304

Locations: 🇺🇸
Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 28 locations

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

Phase 1

Withdrawn

Conditions: Acute Myeloid Leukemia

Interventions: Drug: ERAS-007
Drug: ERAS-601
Drug: Gilteritinib

First Posted Date: 2022-03-15

Last Posted Date: 2022-06-15

Lead Sponsor: Erasca, Inc.

Registration Number: NCT05279859

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Texas Oncology, Dallas, Texas, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)

Phase 1

Active, not recruiting

Conditions: Glioblastoma Multiforme

Interventions: Drug: ERAS-801

First Posted Date: 2022-02-03

Last Posted Date: 2024-01-31

Lead Sponsor: Erasca, Inc.

Target Recruit Count: 52

Registration Number: NCT05222802

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 5 locations

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Phase 1

Active, not recruiting

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Metastatic Colorectal Cancer

Interventions: Drug: ERAS-007
Drug: Encorafenib
Drug: Palbociclib
Drug: Cetuximab

First Posted Date: 2021-09-09

Last Posted Date: 2024-03-04

Lead Sponsor: Erasca, Inc.

Target Recruit Count: 102

Registration Number: NCT05039177

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸
University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States

and more 11 locations

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Phase 1

Completed

Conditions: Advanced Non-squamous Non-small-cell Lung Cancer

Interventions: Drug: ERAS-007
Drug: ERAS-601
Drug: Osimertinib
Drug: Sotorasib

First Posted Date: 2021-07-13

Last Posted Date: 2023-07-25

Lead Sponsor: Erasca, Inc.

Target Recruit Count: 24

Registration Number: NCT04959981

Locations: 🇺🇸
Hackensack University Medical Center (John Theurer Cancer Center), Hackensack, New Jersey, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Research Institute, Boston, Massachusetts, United States

and more 8 locations

A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Drug: ERAS-007
Drug: ERAS-601

First Posted Date: 2021-04-29

Last Posted Date: 2024-08-27

Lead Sponsor: Erasca, Inc.

Target Recruit Count: 200

Registration Number: NCT04866134

Locations: 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇺🇸
Sarah Cannon Research Institute (HealthONE), Denver, Colorado, United States
🇺🇸
Mary Crowley Cancer Research, Dallas, Texas, United States

and more 2 locations

A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Drug: ERAS-601
Drug: Cetuximab
Drug: Pembrolizumab

First Posted Date: 2020-12-17

Last Posted Date: 2024-08-27

Lead Sponsor: Erasca, Inc.

Target Recruit Count: 200

Registration Number: NCT04670679

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Washington University, Saint Louis, Missouri, United States

and more 12 locations

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy